Objective To provide evidence-based recommendations regarding the diagnosis and
management of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis …

The goal of obesity management is to improve health. Sustained weight loss of more than
10% overall bodyweight improves many of the complications associated with obesity (eg …

Background Retatrutide (LY3437943) is an agonist of the glucose-dependent insulinotropic
polypeptide, glucagon-like peptide 1, and glucagon receptors. Its dose–response …

Background Obesity is a chronic disease that results in substantial global morbidity and
mortality. The efficacy and safety of tirzepatide, a novel glucose-dependent insulinotropic …

Non-alcoholic fatty liver disease (NAFLD) has become an epidemic, much like other non-
communicable diseases (NCDs), such as cancer, obesity, diabetes, and cardiovascular …

The American Diabetes Association (ADA)“Standards of Care in Diabetes” includes the
ADA's current clinical practice recommendations and is intended to provide the components …

Background Weight reduction is essential for improving health outcomes in people with
obesity and type 2 diabetes. We assessed the efficacy and safety of tirzepatide, a glucose …

Importance Hepatocellular carcinoma (HCC) is the sixth most common malignancy and
fourth leading cause of cancer-related death worldwide. Recent advances in systemic and …

Background Observational studies suggest that bariatric–metabolic surgery might greatly
improve non-alcoholic steatohepatitis (NASH). However, the efficacy of surgery on NASH …

Importance Cirrhosis affects approximately 2.2 million adults in the US. From 2010 to 2021,
the annual age-adjusted mortality of cirrhosis increased from 14.9 per 100 000 to 21.9 per …